Altshuler Shaham Ltd Has $816,000 Position in Kamada Ltd. (NASDAQ:KMDA)

Altshuler Shaham Ltd lessened its holdings in Kamada Ltd. (NASDAQ:KMDA) by 49.9% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 132,935 shares of the biotechnology company’s stock after selling 132,330 shares during the period. Altshuler Shaham Ltd’s holdings in Kamada were worth $816,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. Meitav Investment House Ltd. increased its stake in Kamada by 17.2% in the 3rd quarter. Meitav Investment House Ltd. now owns 76,835 shares of the biotechnology company’s stock valued at $412,000 after buying an additional 11,284 shares during the period. EWA LLC purchased a new position in shares of Kamada during the 4th quarter valued at $68,000. Finally, Y.D. More Investments Ltd acquired a new position in shares of Kamada in the third quarter worth $75,000. Hedge funds and other institutional investors own 20.38% of the company’s stock.

Kamada Trading Down 3.1 %

NASDAQ KMDA traded down $0.18 during trading on Thursday, reaching $5.56. The company’s stock had a trading volume of 26,749 shares, compared to its average volume of 22,688. The stock has a market capitalization of $319.59 million, a PE ratio of 38.27 and a beta of 1.05. Kamada Ltd. has a 1-year low of $4.08 and a 1-year high of $6.53. The business has a 50-day moving average price of $5.57 and a 200-day moving average price of $5.51.

Kamada (NASDAQ:KMDA) last released its quarterly earnings data on Wednesday, March 6th. The biotechnology company reported $0.09 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.05 by $0.04. Kamada had a net margin of 5.81% and a return on equity of 5.66%. The business had revenue of $36.43 million during the quarter, compared to analyst estimates of $37.71 million. As a group, analysts expect that Kamada Ltd. will post 0.23 earnings per share for the current year.

Wall Street Analyst Weigh In

Separately, HC Wainwright reissued a “buy” rating and set a $11.00 price objective on shares of Kamada in a research report on Thursday.

Kamada Company Profile

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.